Summary The first source describes the resignation of all seven independent directors from 23andMe's board due to disagreements with CEO Anne Wojcicki regarding the company's strategic direction. These disagreements stemmed from Wojcicki's proposal to take the company private, which the board rejected due to a lack of a premium offer to shareholders. The second source discusses the potential future of 23andMe's genetic data as the company faces financial challenges and the possibility of going out of business. While the company emphasizes its commitment to privacy and its policy of anonymizing data, concerns remain about the security and potential misuse of this sensitive information, particularly in light of the company's recent data breach and the resignation of its board.